Want to see TSE:AVCR full AI Analyst Report?
AVCR Stock Chart & Stats
C$0.05
>-C$0.01(-8.33%)
At close: 4:00 PM EST
C$0.05
>-C$0.01(-8.33%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.10
Previous CloseN/A
Volume23.00K
Average Volume (3M)51.37K
Market Cap
C$6.58M
Enterprise ValueC$4.86M
Total Cash (Recent Filing)C$210.30K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding101,289,665
10 Day Avg. Volume29,762
30 Day Avg. Volume51,367
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)13.00
Price to Sales (P/S)9.49
P/FCF Ratio-5.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Essentially No DebtA near-zero debt profile materially reduces fixed financial obligations and interest burden, giving management flexibility to prioritize operational recovery or product investment. Over a multi-month horizon this lowers bankruptcy risk and preserves capacity to raise growth capital on less strained terms.
Recurring Platform And Service Revenue MixThe HealthTab platform and recurring service fees create a structurally stickier revenue stream versus one-off tests. Recurring software/connectivity and program-administration revenues support predictable unit economics and potential margin expansion as site counts and utilization scale over several months.
Positioned In Pharmacy Point-of-care Testing MarketAvricore operates in a durable structural trend toward decentralized, pharmacy-delivered diagnostics and chronic-disease monitoring. Embedded pharmacy access and in‑store workflows create distribution advantages and potential network effects that can support steady program rollouts and data-driven services over the medium term.
Bears Say
Severe Revenue Decline (TTM)A roughly 73% TTM revenue collapse is structurally harmful: it reduces leverage from scale, erodes pricing power, and makes fixed-cost absorption harder. If sustained, the decline undermines the unit economics of in-pharmacy programs and materially increases the probability of continued financing dependence.
Operating Cash Flow Turned Negative And WorsenedThe shift to negative operating cash flow signals the business is consuming rather than generating cash, forcing reliance on external funding. Over a 2–6 month horizon this constrains investment in sales and product, raises dilution risk from financing, and limits ability to execute recovery plans.
Material Equity Erosion Raises Financing RiskA collapsing equity base reduces the firm’s loss-absorbing capacity and raises the likelihood of dilutive capital raises. This structural capital weakness can impair long-term partnerships, bargaining with suppliers, and investor confidence, increasing execution risk absent a sustained revenue recovery.
Avricore Health News
AVCR FAQ
What was Avricore Health Inc.’s price range in the past 12 months?
Avricore Health Inc. lowest stock price was C$0.04 and its highest was C$0.10 in the past 12 months.
What is Avricore Health Inc.’s market cap?
Avricore Health Inc.’s market cap is C$6.58M.
When is Avricore Health Inc.’s upcoming earnings report date?
Avricore Health Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 53 days.
How were Avricore Health Inc.’s earnings last quarter?
Currently, no data Available
Is Avricore Health Inc. overvalued?
According to Wall Street analysts Avricore Health Inc.’s price is currently Overvalued.
Does Avricore Health Inc. pay dividends?
Avricore Health Inc. does not currently pay dividends.
What is Avricore Health Inc.’s EPS estimate?
Avricore Health Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avricore Health Inc. have?
Avricore Health Inc. has 101,289,665 shares outstanding.
What happened to Avricore Health Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avricore Health Inc.?
Currently, no hedge funds are holding shares in TSE:AVCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avricore Health Inc.
Avricore Health Inc. operates within Canada, specializing in health data management and point-of-care technological solutions. Their primary offering is HealthTab, a precise, laboratory-quality diagnostic testing system designed for use in pharmacies. This enterprise maintains key alliances with prominent organizations such as Shoppers Drug Marts and Abbott. Established in 1996 and headquartered in Vancouver, Canada, the company previously operated as Vanc Pharmaceuticals Inc., adopting its current name, Avricore Health Inc., in October 2018.
Technical Analysis
BioMark Diagnostics
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
―
PanGenomic Health, Inc. Class A
―
Options Prices
Currently, No data available
---